MCap $73 Million / Cash $35 Million / NDA submission for a BIG drug this or next Q / Another 3 Drugs in Phase 3 trials = One of the CHEAPEST biotech in the entire sector a potential 10 Bagger here guys .GL Scynexis (SCYX) Market Cap $73 Million Cash $35 Million Price $7.40 Shares Out 9.9 Million Presentation https://d1io3yog0oux5.cloudfront.ne...SCYX+Corporate+Presentation+-+May+2020(1).pdf Scynexis' lead drug scores in vaginal yeast infection trial https://endpts.com/scynexis-lead-drug-scores-in-vaginal-yeast-infection-trial/ Ibrexafungerp,if approved, could end up as the only oral alternative to fluconazole approved for acute VVC infections, although Mycovia is testing another therapy, VT-1161, for patients with recurrent VVC, Needham’s Alan Carr wrote in a note, adding that he expects ibrexafungerp to launch in 2021. “Our data suggest 15% of pts return to their physician because existing treatments are inadequate…physician interest in a new drug is high and we estimate even modest (25%) penetration of the second-line setting generates peak sales (for ibrexafungerp) of over $450M.”
